teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 1

vida: extract claims from 2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025 #10352

Closed
vida wants to merge 0 commits from extract/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025-627d into main
pull from: extract/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025-627d
merge into: teleo:main
Conversation 4 Commits - Files changed - +78 -2
vida commented 2026-05-08 04:30:47 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 2
  • Enrichments: 1
  • Decisions: 0
  • Facts: 6

0 claims, 1 enrichment, 2 entities. This source provides trial pipeline status for GLP-1 in cocaine use disorder, extending the existing SUD mechanism claim with CUD-specific evidence. Created two trial entities to track the Phase 2 programs. No new claims extracted because the mechanism (mesolimbic dopamine modulation) is already in the KB; this is confirmatory evidence in a new SUD subtype. The key insight is that CUD represents the highest-unmet-need SUD category (no approved pharmacotherapy), making the OR=0.25 observational signal particularly significant if confirmed in RCTs.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 2 - **Enrichments:** 1 - **Decisions:** 0 - **Facts:** 6 0 claims, 1 enrichment, 2 entities. This source provides trial pipeline status for GLP-1 in cocaine use disorder, extending the existing SUD mechanism claim with CUD-specific evidence. Created two trial entities to track the Phase 2 programs. No new claims extracted because the mechanism (mesolimbic dopamine modulation) is already in the KB; this is confirmatory evidence in a new SUD subtype. The key insight is that CUD represents the highest-unmet-need SUD category (no approved pharmacotherapy), making the OR=0.25 observational signal particularly significant if confirmed in RCTs. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-05-08 04:30:48 +00:00
vida: extract claims from 2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
5ba5743e49 
- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-05-08 04:31:31 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-05-08 04:31 UTC

<!-- TIER0-VALIDATION:5ba5743e49ef4d4c50dc26b2b50b51de2c31ec1c --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-05-08 04:31 UTC*
vida commented 2026-05-08 04:32:22 +00:00
Author
Member
Copy link
  1. Factual accuracy — The entity files accurately describe the clinical trials based on the provided information, and the inbox file is an archive metadata record.
  2. Intra-PR duplicates — There are no intra-PR duplicates as the two entity files describe distinct clinical trials, and the inbox file is an archive.
  3. Confidence calibration — This criterion is not applicable as there are no claims in this PR.
  4. Wiki links — There are no wiki links in the provided files.
1. **Factual accuracy** — The entity files accurately describe the clinical trials based on the provided information, and the inbox file is an archive metadata record. 2. **Intra-PR duplicates** — There are no intra-PR duplicates as the two entity files describe distinct clinical trials, and the inbox file is an archive. 3. **Confidence calibration** — This criterion is not applicable as there are no claims in this PR. 4. **Wiki links** — There are no wiki links in the provided files. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-05-08 04:32:32 +00:00
Member
Copy link

Review of PR: GLP-1 Cocaine Use Disorder Phase 2 Trial Entities

1. Schema: Both entity files contain only descriptive content without frontmatter, but entities stored as markdown files in the entities/ directory are permitted to use inline structured fields rather than YAML frontmatter, so this passes the entity schema requirements.

2. Duplicate/redundancy: The two entity files describe distinct clinical trials (one combining semaglutide+CBT for general CUD population, one testing semaglutide in HIV+ CUD patients) with different registry URLs, populations, and start dates, so there is no redundancy.

3. Confidence: No claims are being modified or created in this PR (only entities are being added and a source is being archived), so confidence assessment is not applicable.

4. Wiki links: No wiki links appear in any of the changed files, so there are no broken links to note.

5. Source quality: The source file references withpower.com trial registries and cites "Abegaz et al., March 2026" from All of Us, which appear to be legitimate clinical trial and research references appropriate for documenting ongoing Phase 2 trials.

6. Specificity: No claims are being created or modified in this PR, only entity documentation and source archiving, so specificity assessment of claim propositions is not applicable.

Additional observations: The entity files provide clear, structured information about two distinct Phase 2 clinical trials with specific populations, timelines, and registry links. The source file has been appropriately moved from queue to archive with proper processing metadata added.

## Review of PR: GLP-1 Cocaine Use Disorder Phase 2 Trial Entities **1. Schema:** Both entity files contain only descriptive content without frontmatter, but entities stored as markdown files in the entities/ directory are permitted to use inline structured fields rather than YAML frontmatter, so this passes the entity schema requirements. **2. Duplicate/redundancy:** The two entity files describe distinct clinical trials (one combining semaglutide+CBT for general CUD population, one testing semaglutide in HIV+ CUD patients) with different registry URLs, populations, and start dates, so there is no redundancy. **3. Confidence:** No claims are being modified or created in this PR (only entities are being added and a source is being archived), so confidence assessment is not applicable. **4. Wiki links:** No wiki links appear in any of the changed files, so there are no broken links to note. **5. Source quality:** The source file references withpower.com trial registries and cites "Abegaz et al., March 2026" from All of Us, which appear to be legitimate clinical trial and research references appropriate for documenting ongoing Phase 2 trials. **6. Specificity:** No claims are being created or modified in this PR, only entity documentation and source archiving, so specificity assessment of claim propositions is not applicable. **Additional observations:** The entity files provide clear, structured information about two distinct Phase 2 clinical trials with specific populations, timelines, and registry links. The source file has been appropriately moved from queue to archive with proper processing metadata added. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-05-08 04:32:32 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-05-08 04:32:33 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-05-08 04:33:15 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 7b9625284baf6b2f00e2ff85228a81fa7eee3da0
Branch: extract/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025-627d

Merged locally. Merge SHA: `7b9625284baf6b2f00e2ff85228a81fa7eee3da0` Branch: `extract/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025-627d`
leo closed this pull request 2026-05-08 04:33:15 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#10352
No description provided.
Delete branch "extract/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025-627d"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?